MEM SLOAN-KETTERING is a generic drug manufacturer focused on Oncology, Neurology.
MEM SLOAN-KETTERING's Key Drugs
MEM SLOAN-KETTERING's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
MEM SLOAN-KETTERING's Recent FDA Approvals
New NDA/BLA approvals for MEM SLOAN-KETTERING over the last two years — novel drugs only, excluding generics and label supplements.
MEM SLOAN-KETTERING's Therapeutic Areas
MEM SLOAN-KETTERING's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
MEM SLOAN-KETTERING's Top Competitors
MEM SLOAN-KETTERING's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
MEM SLOAN-KETTERING Pipeline Snapshot
Active clinical trials for MEM SLOAN-KETTERING across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2016-12-08
- Latest
- 2016-12-08
- Applications
- 1